Takeda Confident As Dengue Vaccine Shows Benefits Three Years Out
Protection Regardless Of Prior Infection
New long-term Phase III data for Takeda's candidate dengue vaccine show continued protection against illness and hospitalization, regardless of previous exposure, out to the three-year mark following the two-dose jab.
